Hepatic artery injection of 131I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study

Wu, Lu; Yang, Yue; Ge, Naijian; Shen, Shuqun; Liang, Jun; Wang, Yi; Zhou, Weiping; Shen, Feng; Wu, Mengchao

doi:10.1007/s00259-012-2145-5

Cited by 29 publications

(25 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metuzumab, as an anti-CD147 mAb, may induce adverse side effects in liver and blood compartments; however, toxicity study results showed that it was well tolerated in rat and monkey models. Some clinical trials also suggested that anti-CD147 therapy appears to be a safe and effective treatment of cancer (23,24,(43)(44)(45). Overall, careful attention should be focused on monitoring blood, liver, and muscle function impairments in clinical trials.…”

Section: Discussionmentioning

confidence: 99%

Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody

Zhang

Sun³

et al. 2015

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Metuzumab is an affinity-optimized and nonfucosylated anti-CD147 human-mouse chimeric IgG1 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC). The purpose of this study was to characterize the pharmacokinetics, safety, and antitumor activities of metuzumab in mouse, rat, and monkey. The ADCC activity was assessed by a lactate dehydrogenase release assay. The pharmacokinetics of metuzumab were determined in Sprague-Dawley rats and in cynomolgus monkeys. Single-and repeat-dose toxicology studies of the i.v. administration of high-dose metuzumab were conducted in cynomolgus monkeys. Mice bearing human tumor xenografts were used to evaluate the antitumor efficacy of metuzumab. The ADCC potency of metuzumab was enhanced compared with the nonglycoengineered parental antibody. Metuzumab also effectively inhibited tumor growth in A549 and NCI-H520 xenograft models. In the monkey model, the total clearance of metuzumab decreased with increasing dose. The nonspecific clearance in monkeys was estimated to be 0.53 to 0.92 mL/h/kg. In single-and repeat-dose toxicology studies in cynomolgus monkeys, metuzumab did not induce any distinct or novel adverse findings and was well tolerated at all tested doses. These preclinical safety data facilitated the initiation of an ongoing clinical trial of metuzumab for the treatment of non-small cell lung cancer

show abstract

Section: Discussionmentioning

confidence: 99%

Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody

Zhang

Sun³

et al. 2015

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…The full-texts were carefully evaluated. They were published from 2007 to 2015, and all had investigated TACE plus 131 I-metuximab therapy (1112131920212223). Totally 1121 patients were included in these studies.…”

Section: Resultsmentioning

confidence: 99%

“…Among those, 546 patients underwent TACE plus 131 I-metuximab therapy, as compared with 575 patients who received TACE alone. There were: 3 RCTs (112223), and 5 non-RCTs (1213192021) (Fig. 1).…”

Section: Resultsmentioning

confidence: 99%

“…All the studies described the mean age of their patients; 7 studies (11121319202123) described severity of liver disease by Child-Pugh score. The anticancer drugs used were cyclosporin A (11), cisplatin (22), fluorouracil (121322), mitomycin-C (13), and adriamycin (122223), and epirubicin (1920). Usually, lipiodol was mixed with the drugs at a uniform dosage or a dosage calculated according to tumor size before the procedure.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Transcatheter Arterial Chemoembolization Plus¹³¹I-Labelled Metuximab versus Transcatheter Arterial Chemoembolization Alone in Intermediate/Advanced Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

et al. 2016

View full text Add to dashboard Cite

ObjectiveThe aim of the study was to compare transcatheter arterial chemoembolization (TACE) plus 131I-labelled metuximab with TACE alone for hepatocellular carcinoma (HCC).Materials and MethodsA comprehensive search was conducted in PubMed, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Chinese BioMedical Literature Database with published date from the earliest to February 29th, 2016. No language restrictions were applied, but only prospective randomized controlled trials (RCTs) or non-RCTs were eligible for a full-text review. The primary outcome was the overall survival (OS) and effective rate (the rate of partial atrophy or complete clearance of the tumor lesion). The odds ratios (ORs) were combined using either the fixed-effects model or random-effects model.ResultsEight trials (3 RCTs and 5 non-RCTs) were included, involving a total of 1121 patients. Patients receiving combined therapy of TACE plus 131I-labelled metuximab showed significant improvement in effective rate {OR = 4.00, (95% confidence interval [CI]: 2.40–6.66), p < 0.001}, 1-year OS (OR = 2.03 [95% CI: 1.55–2.67], p < 0.001) and 2-year OS (OR = 2.57 [95% CI: 1.41–4.66], p = 0.002].ConclusionTACE plus 131I-labelled metuximab is more beneficial for treating advanced HCCs than TACE alone in terms of tumor response and OS. Large, multi-center, and blinded randomized trials are required to confirm these findings.

show abstract

“…156 In another Hepatocellular treatment trial, this combination had acceptable outcomes for intermediate stage HCC and it was suggested as a therapeutic option for this stage. 157 In another study efficacy of the combination of TACE and brachytherapy was compared to TACE alone. The study group had combination of loboplatin-TACE and 125 I seeds as radiotherapy.…”

Section: Chemotherapy and Radiotherapymentioning

confidence: 99%

New modalities of treatment for hepatocellular carcinoma

Behnagh

Rezaei

Jahannia

et al. 2017

J. contemp. med. sci.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the second most common cause of death from cancer worldwide. Managing HCC is difficult. However, there are many treatment options available such as liver transplantation, radiotherapy, different ablative techniques, surgery, trans-arterial chemoembolization (TACE) and systemic therapy. These treatments did not show the promising responses and the recurrence rate is still high. On the other hand, there are some new treatments such as immunotherapy, gene therapy, combination of different therapies, Chinese traditional therapies and new targeted therapies. The aim of this study is to review both the recent changes in the common therapies and newly developed therapies of HCC.

show abstract

Hepatic artery injection of 131I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study

Cited by 29 publications

References 24 publications

Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody

Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody

Transcatheter Arterial Chemoembolization Plus¹³¹I-Labelled Metuximab versus Transcatheter Arterial Chemoembolization Alone in Intermediate/Advanced Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

New modalities of treatment for hepatocellular carcinoma

Contact Info

Product

Resources

About

Hepatic artery injection of 131I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study

Cited by 29 publications

References 24 publications

Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody

Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody

Transcatheter Arterial Chemoembolization Plus131I-Labelled Metuximab versus Transcatheter Arterial Chemoembolization Alone in Intermediate/Advanced Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

New modalities of treatment for hepatocellular carcinoma

Contact Info

Product

Resources

About

Transcatheter Arterial Chemoembolization Plus¹³¹I-Labelled Metuximab versus Transcatheter Arterial Chemoembolization Alone in Intermediate/Advanced Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis